SCHEMBL3759980

SCHEMBL3759980

Cc1ccn[c]c1-c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.36
NOTUM Q6P988 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
RAB9A P51151 4/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
KMT2A Q03164 1/20 0.32
MTOR P42345 1/20 0.32
ADK P55263 1/20 0.32
NISCH Q9Y2I1 1/20 0.32
CYP2A6 P11509 1/20 0.32
CYP2B6 P20813 1/20 0.32
ATM Q13315 1/20 0.32
NPC1 O15118 3/20 0.32
TSHR P16473 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435001 0.77 LRRK2 (0.39) NOTUMRAB9AALDH1A1MTORADK
SCHEMBL2399248 0.75 NOTUM (0.34) NOTUML3MBTL1RAB9AALDH1A1MEN1
SCHEMBL3758939 0.75 ALDH1A1 (0.37) NOTUMALDH1A1KDM4EMEN1POLB
SCHEMBL3751748 0.75 BACE1 (0.38) NOTUML3MBTL1RAB9AALDH1A1KDM4E
SCHEMBL3759693 0.75 CYP2A6 (0.37) NOTUML3MBTL1RAB9AALDH1A1KDM4E
SCHEMBL28361802 0.75 KDM4E (0.46) PDE10AL3MBTL1RAB9AALDH1A1KDM4E
SCHEMBL3754786 0.75 LMNA (0.36) NOTUMRAB9AALDH1A1KDM4EMEN1
SCHEMBL3766619 0.75 CA12 (0.38) L3MBTL1RAB9AALDH1A1KDM4EMEN1
SCHEMBL3758958 0.75 SMN1; SMN2 (0.33) NOTUML3MBTL1RAB9AALDH1A1MEN1
SCHEMBL7570634 0.73 SMN1; SMN2 (0.40) L3MBTL1RAB9AALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed
EP-0441447-B1 Carbonylation catalyst process SHELL INT RESEARCH (NL) 1994-11-30 EP disclosed
EP-0441445-B1 Preparation of amides SHELL INT RESEARCH (NL) 1994-05-04 EP disclosed
US-5166116-A Coordination catalysts of phosphine, group 8 metal, protons and sulfonate SHELL OIL COMPANY (US) 1992-11-24 US disclosed
US-5128475-A PREPARATION OF AMIDES SHELL OIL COMPANY (US) 1992-07-07 US disclosed
US-5124300-A Group 8 metal, aromatic phosphine, proton source, tertiary amine SHELL OIL COMPANY (US) 1992-06-23 US disclosed
US-5103043-A CARBONYLATION CATALYST SYSTEM SHELL OIL COMPANY (US) 1992-04-07 US disclosed
EP-0441447-A1 Carbonylation catalyst process SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-08-14 EP disclosed
EP-0441446-A1 Carbonylation catalyst system SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-08-14 EP disclosed
EP-0441445-A2 Preparation of amides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-08-14 EP disclosed
US-5028576-A Carbonylation catalyst system SHELL OIL COMPANY (US) 1991-07-02 US disclosed
EP-0423866-A1 Phosphorous compounds SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-04-24 EP disclosed
EP-0386834-A1 Carbonylation catalyst system SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PDE10A 2262/4885NOTUM 1802/4885L3MBTL1 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.